Trump’s IVF Executive Order: What You Need to Know [Updated Feb. 2026]

We run through the timeline of what’s happened since the Executive Order below – and will keep this updated as the situation evolves.

February 2026 Update – TrumpRx Platform Launches

On February 5, 2026, the Trump administration launched TrumpRx.gov, a new government platform designed to provide Americans with direct access to lower-cost prescription medications. The platform is part of the broader effort connected to the February 2025 IVF executive order aimed at reducing the cost of fertility care and improving access.

According to the White House, the platform includes reduced pricing on several commonly used fertility medications and may expand to include additional drugs over time. As with many federal healthcare initiatives, the long-term impact and availability of these programs will continue to evolve.

For patients planning fertility care, this reinforces the importance of continuing to move forward rather than waiting for potential policy changes.

Supporting Patients in the Meantime

While national policy continues to evolve, The Prelude Network® has continued focusing on ways to help make fertility treatment more manageable today, including the cost and coordination of fertility medications.

One example is inspireRx, Prelude’s pharmacy benefits platform designed to simplify the prescription process and help patients access medications more affordably through a network of trusted pharmacies.

Through inspireRx, patients may benefit from:

• Potential savings on fertility medications
• Help navigating insurance benefits and prior authorizations
• Convenient delivery or expedited pickup options
• Access to pharmacist and clinical support
• Updates throughout the prescription process

As we continue monitoring federal IVF policy developments, our goal remains the same: helping patients move forward with clarity, support, and practical resources. Learn more at the inspireRx website.

October 2025 – White House Releases IVF Policy Fact Sheet

On October 16, the White House issued a detailed fact sheet outlining the administration’s initiatives to reduce IVF costs and expand access. Highlights include a most-favored-nation (MFN) drug pricing agreement with EMD Serono, savings on common fertility medications through TrumpRx.gov; plans to manufacture IVF drugs in the U.S. for the first time; and the inclusion of a lower-cost fertility drug in the FDA’s expedited National Priority Review Voucher program.

The fact sheet also reaffirms a new legal pathway for employers to offer standalone fertility benefits outside of traditional health insurance — a move that could expand IVF coverage, especially among small and mid-sized businesses.

October 2025 – White House Announces IVF Drug Discount and Employer Benefit Option

On October 16, 2025, the Trump administration unveiled its first major follow-up to the February executive order on reducing IVF costs. Speaking from the Oval Office, President Trump announced three primary initiatives aimed at expanding access to fertility care:

• A new agreement with drug manufacturer EMD Serono will reduce the out-of-pocket cost of common IVF medications. Patients who use EMD Serono’s Gonal-f®, Ovidrel®, and Cetrotide® together in a typical IVF cycle will receive an 84% discount off list prices. These medications will be available starting January 2026 via a new government-run direct purchasing platform, TrumpRx.gov.
• EMD Serono also announced it has submitted Pergoveris®, a combination fertility therapy already available in over 70 countries, for expedited FDA review through the National Priority Voucher program. If approved, Pergoveris would offer another option for patients with more complex fertility needs.
• New federal guidance from the Departments of Labor, Treasury, and HHS will allow employers to offer fertility benefits — such as IVF coverage — separately from major medical insurance, similar to how dental or vision benefits are handled. While participation is voluntary, the administration says this option may help smaller businesses offer fertility benefits to employees.

As with earlier steps in this process, The Prelude Network® will continue to follow these developments and keep patients informed as the landscape of fertility care evolves.

August 2025 – Alternative Approaches Discussed: Restorative Reproductive Medicine

The administration also explored restorative reproductive medicine (RRM), an approach promoted by some conservative policy groups.

This method emphasizes addressing underlying health factors that affect fertility through monitoring ovulation and other biological markers, diagnosing and treating conditions such as PCOS and endometriosis, recommending lifestyle or dietary changes (including vitamins and supplements), and using certain medications or surgery.

Critics, including the American College of Obstetricians and Gynecologists (ACOG), point out that while fertility awareness and lifestyle changes can and should play a supportive role alongside standard fertility treatments, many fertility patients already try these methods before ultimately needing medical treatment. RRM also does not fully address the diverse paths to parenthood, particularly in cases involving male infertility, LGBTQ+ family building, or single parenthood by choice.

April 2025 – Policy Recommendations Pending

The executive order directed the Assistant to the President for Domestic Policy to submit policy recommendations within 90 days to protect IVF access and reduce associated costs. As of today, these recommendations are anticipated but have not yet been publicly released.

March 2025 – Inception Meets with White House Staff

On March 27, 2025, the Fertility Providers Alliance (FPA) met with White House staff. The meeting focused on essential IVF policies and how they’d significantly impact families across the nation. Some policies presented include:

March 2025 – Public Statements by President Trump

On March 26, during a Women’s History Month event at the White House, President Trump announced the formation of the Republican Women’s Caucus in Congress. While this announcement was separate from his IVF-related executive order, it reflects ongoing attention to reproductive issues in the political sphere.

February 2025 – Executive Order & Policy Review

In February 2025, President Trump signed an executive order aimed at reducing the cost of in vitro fertilization (IVF). The order directs the Assistant to the President for Domestic Policy to provide Trump with a list of policy recommendations aimed at protecting IVF access and lowering out-of-pocket expenses and health plan costs.

It is encouraging to see national support for IVF, as 1 in 6 couples in the U.S. face fertility challenges. However, it’s important to note that this executive order does not guarantee that a policy will be implemented immediately. The recommendations for IVF-related policies are still in development.

Because these recommendations are still under review, it’s uncertain how — or if — they will ultimately be implemented, and any changes could take months or even years to take effect. For those hoping to build a family, timing is critical. Beginning treatment now ensures you don’t put your plans on hold while waiting for outcomes that remain unclear.

We run through the timeline of what’s happened since the Executive Order below – and will keep this updated as the situation evolves.

• Requiring IVF treatment and services to be part of each state’s Medicaid coverage
• Including fertility treatment and preservation services as Essential Health Benefits (EHB) for ACA plans
• Creating a health workforce grant to increase the number of reproductive endocrinologists and embryologists
• Expanding VA Health and TRICARE to include fertility preservation and infertility services for non-service-related injuries